Compare TKO Group Holdings Inc (TKO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TKO Group Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? TKO Group Holdings Inc trades at $178.01 (market cap $13.28B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: TKO Group Holdings Inc is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold TKO Group Holdings Inc for 30 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TKO | XBI | |
|---|---|---|
Market Cap | $13.28B | $10.11B |
Volume | 857,653 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $224.96 | $169.55 |
52-Week Low | $175.58 | $104.99 |
Typical Hold Time | 30 Days | 38 Days |
Enterprise Value | $17.64B | — |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TKO trades at $181.63, up 1.67% today, but technical indicators signal a bearish trend with the stock near support at $180. Fundamentally, the company shows revenue growth with 2026 revenue projected at $5.3B and net income of $230M, though its high P/E of 63.73 indicates premium valuation. Recent Q2 2026 earnings missed expectations, but the company raised full-year guidance, reflecting operational strength. A dividend of $0.79 is scheduled for payment on September 30, 2026, adding income appeal.
The outlook for TKO is mixed; strong analyst buy consensus (89.47%) and a $227 price target suggest 25% upside, driven by media rights and live events. However, risks include competitive pressures, earnings volatility, and the stock's bearish technical posture. Investors should weigh solid fundamentals against near-term price weakness and market sentiment.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
